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Nuclear Orphan Receptors Minireview
Control Cholesterol Catabolism
Enterocytes protect themselves from the detergent
actions of intracellular bile acids by expressing the ileal
bile acid binding protein (encoded by the IBABP gene),
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which facilitates the movement of the detergents across
the cell and their secretion into the portal circulation.
Over the last three decades, much progress has been When they reach the liver, the bile acids are taken up
made in understanding the mechanisms and regulation by a transporter on the apical surface of the hepatocyte,
of the cholesterol supply pathways that cells and tissues and thereafter they are secreted into the bile duct to
use to sate their demands for this essential membrane begin another round of the enterohepatic cycle.
component. But how does the body get rid of excess Bile acids thus perform several functions in lipid physi-
cholesterol and by what means is the catabolic process ology. First, their synthesis provides a disposal mecha-
regulated? These questions are of medical as well as nism to counterbalance the cholesterol synthesis path-
scientific importance because controlled elimination is way and allow homeostasis to be achieved. Second,
one of the body's chief defenses against cholesterol their detergent actions are essential within the intestine
accumulation and consequent heart attacks. Several for the uptake of hydrophobic nutrients like fat-soluble
recent papers address the essence of these questions vitamins, and within the liver for the solubilization of
and reveal potential physiological roles for three nuclear metabolites like bilirubin. Third, as detailed below, inter-
orphan receptors, the LXRa (or more properly NR1H2; mediates and endproducts of the bile acid pathway reg-
Nuclear Receptors Nomenclature Committee, 1999), ulate the expression of genes that synthesize choles-
CPF (NR5A2), and FXR (NR1H4) proteins, in controlling terol, fatty acids, and bile acids themselves.
the conversion of cholesterol into its bulk catabolic Pathways of Bile Acid Synthesis
products, namely, the bile acids. In the early 1940s Konrad Bloch fed radiolabeled choles-
Included in this body of work is a paper in the May terol to dogs and observed its conversion to polar me-
issue of Molecular Cell in which Wang et al. (1999) show tabolites that were excreted in the stool. These were
that chenodeoxycholate, a bile acid derived from cho- identified as bile acids, which generally have three fewer
lesterol, interacts with a nuclear hormone receptor, FXR, carbon atoms than cholesterol. They also have multiple
to suppress transcription from a reporter gene. In two
papers appearing in Science, Makishima et al. (1999)
and Parks et al. (1999) show that chenodeoxycholate
interacts with FXR to suppress transcription of the cho-
lesterol 7a-hydroxylase gene (Cyp7a), whose product
catalyzes the rate-limiting step in bile acid synthesis
from cholesterol. Ligand-activated FXR also induces
transcription of IBABP, a gene encoding a transport
protein that facilitates reuptake of bile acids in the small
intestine. Together these results suggest that choles-
terol metabolites control their synthesis in the liver
through feedback suppression of Cyp7a and their trans-
port across the intestine through feedforward induction
of IBABP.
Physiology of Cholesterol Catabolism
About one-half gram of cholesterol is metabolized in the
adult human liver each day by conversion into bile acids,
predominantly cholate and chenodeoxycholate (Figure
1). After conjugation with the amino acids glycine or
taurine, these endproducts are secreted via the bile
ducts and gallbladder into the lumen of the small intes-
tine where they act as detergents to emulsify dietary
lipids and fat-soluble vitamins. These emulsified nutri-
ents are taken up by enterocytes that line the proximal
segments of the gut while bile acids continue to move Figure 1. Bile Acid Physiology
distally. When the bile acids reach the end of the small Bile acids are synthesized in the liver and secreted via the bile duct
intestine, they are taken up by a polytopic membrane and gallbladder into the lumen of the small intestine. They solubilize
and thus facilitate the uptake of dietary lipids in the initial segmentprotein termed the ileal bile acid transporter (encoded
of the small intestine and then a majority are transported acrossby the IBAT gene). About 95% of bile acids are retrieved
enterocytes lining the distal segment of the gut by the actions ofby this route; the remaining 5% are lost to the colon
the ileal bile acid transporter (IBAT) and the ileal bile acid binding
and ultimately excreted from the body. The unrecovered protein (IBABP). These bile acids are returned to the liver via the
bile acids are replaced by new synthesis in the liver, portal circulation. About 5% of the bile acid pool (0.5 g/day) escapes
and this production (z0.5 g/day) accounts for almost uptake and is excreted via the colon. This amount is replaced by
new synthesis in the liver.all cholesterol breakdown in the body.
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Figure 2. Pathways of Bile Acid Synthesis
Two pathways produce 7a-hydroxylated bile
acids in the liver. The classical pathway be-
gins with a cholesterol substrate and is initi-
ated by cholesterol 7a-hydroxylase, the
product of the Cyp7a gene. The alternate
pathway begins after the conversion of cho-
lesterol to one of several oxysterol substrates,
which are then acted upon by oxysterol 7a-
hydroxylase, the product of the Cyp7b gene.
The 7a-hydroxylated intermediates arising
from both enzymes are subsequently con-
verted via multiple steps into primary bile
acids like cholate and chenodeoxycholate.
hydrophilic substituents that render them water soluble inactivating oxysterols. When this pathway is disabled
by mutation of the oxysterol 7a-hydroxylase gene, oxy-and provide detergent properties (Figure 2). Workers
sterols accumulate to very high levels and disrupt geneover the ensuing 50 years elucidated the individual bio-
expression in the liver. Some of these compounds turnchemical steps of the pathway by which cholesterol
off the transcription of genes specifying lipid-metaboliz-was converted into bile acids (reviewed in Russell and
ing enzymes while others turn on genes in this network.Setchell, 1992). The rate-limiting step was assigned to
For example, the addition of 25-hydroxycholesterol tothe first enzyme in this pathway, cholesterol 7a-hydroxy-
cells or overexpression of the gene encoding the biosyn-lase. This enzyme is repressed by products of the path-
thetic enzyme for this oxysterol blocks the activation ofway like chenodeoxycholate and cholate. In some spe-
sterol regulatory element binding proteins or SREBPscies, like rats and mice, it is activated in a feedforward
(Lund et al., 1998). SREBPs are bHLH-Zip transcriptionmanner by dietary cholesterol.
factors that regulate the expression of many genes inDuring the last ten years, the genes encoding many
the cholesterol supply and fatty acid synthesis pathwaysenzymes in the bile acid synthesis pathway have been
(Brown and Goldstein, 1997). Another oxysterol, 24-isolated, including that for cholesterol 7a-hydroxylase
hydroxycholesterol, enhances the transcription of sev-(Cyp7a), and mice lacking one or more of these genes
eral genes by activating a nuclear receptor.have been produced. Studies of knockout mice have
LXRa, an Oxysterol Receptor, Activatesrevealed consistencies and conundrums (reviewed in
Cyp7a TranscriptionSchwarz et al., 1998). For example, 90% of Cyp7a2/2
When rats and mice consume large amounts of dietarymice die during the first three weeks of life owing to
cholesterol, they respond in part by synthesizing moregeneralized liver failure and deficiencies of fat-soluble
bile acids through the cholesterol 7a-hydroxylase path-vitamins, as expected given the physiological roles of
way. The increase in catabolism is driven by augmentedbile acids described above. Unexpectedly, in the 10%
transcription of the Cyp7a gene. Using elegant combina-of Cyp7a2/2 animals that survive the newborn period,
tions of classical hormone hunting and molecular biolog-these pathological symptoms resolve and 7a-hydroxyl-
ical methods, three groups showed that activation ofated bile acids are present in the survivors. Since a half
the nuclear orphan receptor LXRa by cholesterol metab-
century of research had delineated only one metabolic
olites increased Cyp7a transcription (Janowski et al.,
pathway leading to 7a-hydroxylated bile acids, the bio-
1996; Forman et al., 1997; Lehmann et al., 1997). Trans-
synthetic origin of these compounds in the Cyp7a2/2 fection studies with the LXRa response element from
mice was a mystery. the Cyp7a gene reveal that the most active ligands in
A second pathway of bile acid synthesis was subse- this regard are the oxysterol 24-hydroxycholesterol, and
quently defined that differed from the classical route 24,25-epoxycholesterol. The epoxide is probably the
in its early steps (Figure 2; Schwarz et al., 1998). This physiologically relevant activator since levels of this ste-
alternate pathway begins with the conversion of choles- rol are high in the liver (Lehmann et al., 1997). On the
terol into one of three oxysterols that contain a hydroxyl other hand, 24-hydroxycholesterol is synthesized in the
group at the 24, 25, or 27 carbon positions on the side brain and rapidly metabolized in the liver (Lund et al.,
chain. These intermediates are substrates for an oxy- 1999).
sterol 7a-hydroxylase (encoded by the Cyp7b locus), The crucial role of LXRa in regulating cholesterol ca-
which produces 7a-hydroxylated oxysterols that are tabolism is dramatically illustrated in mice with a tar-
funneled into the downstream steps of the classical geted disruption of this gene. When fed high cholesterol
pathway to produce bile acids. The importance of the diets, LXRa2/2 mice fail to induce Cyp7a transcription
alternate pathway has been demonstrated in two mam- and accumulate enormous amounts of cholesterol in
malian species: mice and humans. As mentioned above, the liver (Peet et al., 1998). The discoveries that LXRa
this pathway allows mice to survive in the absence of is activated by oxysterols and that Cyp7a is a target for
the classical pathway of bile acid synthesis. Humans this receptor neatly explain one form of feedforward
with mutations in the oxysterol 7a-hydroxylase gene regulation in the classical pathway of bile acid synthesis.
have severe neonatal liver disease even though the cho- CPF, an Orphan Receptor, Also Activates
lesterol 7a-hydroxylase gene is intact. Cyp7a Expression
In addition to producing bile acids, the alternate path- The cholesterol 7a-hydroxylase gene is only expressed
in the liver (Russell and Setchell, 1992). Transfectionway performs another important regulatory function by
Minireview
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studies with the Cyp7a promoter have implicated sev-
eral well-known transcription factors in this tissue-spe-
cific expression (Chiang, 1998); but interpretation of
these results is complicated by the potential artifacts
arising from overexpression. LXRa is expressed in sev-
eral tissues, making it an unlikely mediator of liver-spe-
cific Cyp7a expression.
A strong candidate for this activity has been identified
recently using combined molecular biological and bio-
chemical approaches. Nitta et al. (1999) defined a liver-
specific response element in Cyp7a by DNase I hyper-
sensitivity mapping and then isolated the transcription
factor that interacts with this sequence. cDNA cloning
revealed it to be a mammalian homolog of the Drosophila
fushi tarazu F1 gene, which the authors named CPF
(Cyp7a promoter binding factor). This protein is also
referred to as FTF and LRH-1 in the literature. CPF and
fushi tarazu F1 are orphan nuclear receptors that bind
DNA as monomers and activate the transcription of tar-
Figure 3. Regulatory Loops in Cholesterol Metabolismget genes. Interestingly, they are closely related to ste-
Black arrows indicate metabolic pathways involving cholesterol androidogenic factor 1, which activates genetic pathways
bile acids. The cholesterol 7a-hydroxylase target gene (Cyp7a) isthat convert cholesterol to steroid hormones in the adre-
boxed. Green arrows indicate positive regulation. Red brakes indi-
nal gland and gonads (Parker and Schimmer, 1997). The cate negative regulation.
CPF- and LXRa-binding sites in the Cyp7a promoter are
located about 70 bp apart, which suggests that simulta-
neous binding of both proteins is possible and perhaps to determine the relative contributions of oxysterols ver-
even required for maximal induction of the gene. sus bile acids in regulating gene expression. Whether
FXR, a Bile Acid Receptor, Suppresses antagonism occurs on the DNA, by protein±protein inter-
Cyp7a Transcription action, or by competition for the shared RXR subunit
When the bile acid pool size in an animal is increased by must also be examined.
dietary bile acids, transcription from Cyp7a is decreased Parks et al. (1999) used a fluorescence-based peptide
and that from IBABP is increased. Conversely, reducing binding assay originally described by Zhou et al. (1998)
the bile acid pool size by the use of drugs, or by surgical to identify chenodeoxycholate as a ligand for the FXR
intervention to prevent their return to the liver, causes receptor. This assay measures ligand-dependent inter-
an increase in Cyp7a transcription and a decrease in actions between receptors and fluorescently labeled
IBABP transcription. The new papers in Molecular Cell
peptides derived from the sequences of coactivator pro-
and Science illustrate in convincing fashion that FXR is
teins. It is sensitive, lends itself to automated methods
the bile acid receptor mediating this regulation.
of high throughput screening, and is almost certainly
The common conclusions of these studies can be
being incorporated into the drug discovery programs ofsummarized as follows. First, several bile acids are po-
many large and small pharmaceutical companies.tent and selective activators of FXR-mediated transcrip-
And what about the Makishima et al. (1999) paper?tion, a finding originally reported at several meetings by
These investigators show that FXR is both an activatorCary Weinberger (NIEHS). Second, these compounds
and a suppresser of transcription and that the choiceactivate FXR at concentrations that are found in liver
between these two opposing actions depends on theand intestinal cells. Third, bile acids act through FXR
target gene. Thus, in the presence of bile acids, FXRand not by way of its heterodimerization partner, RXR
suppresses transcription from a Cyp7a reporter gene,(the NR2B class of nuclear receptors). Fourth, more hy-
while it activates transcription from the IBABP promoter.drophilic bile acids, including those conjugated with gly-
It is from these results and the physiological pathwaycine or taurine, require the presence of a plasma mem-
of Figure 1, that we infer FXR is a global regulator ofbrane transporter like IBAT (Figure 1) to gain access to
bile acid metabolism, modulating both synthetic outputFXR in the cell's interior. Fifth, in the presence of bile
in the liver and recycling in the intestine.acids but not in their absence, FXR interacts with mem-
The Next Step?bers of the p160 family of transcriptional coactivator
The multiple roles of metabolites and nuclear orphanproteins. In these respects, bile acid activation of FXR
receptors in regulating cholesterol homeostasis areclosely parallels the actions of ligands for the classical
summarized in Figure 3. A complex interplay of interme-nuclear hormone receptors.
diates and transcription factors serves to regulate theEach paper also makes unique contributions to our
expression of dozens of genes, all in an attempt to con-understanding of the relationship between nuclear re-
trol the levels of potentially toxic but essential hydropho-ceptors and cholesterol catabolism. Wang et al. (1999)
bic molecules.show that FXR and bile acids antagonize the action of
Perhaps the most hotly anticipated experiment in theLXRa on a reporter gene. The significant conclusion of
field will be the characterization of FXR knockout mice.this experiment is that bile acid±mediated suppression
We can only guess at their phenotype. It seems likelyof transcription may occur through antagonism of the
positive actions of LXRa. In the future it will be important that they will suffer unregulated production of bile acids
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through the cholesterol 7a-hydroxylase pathway. Whether
this outcome will result from the loss of feedback regula-
tion mediated by FXR, the unopposed positive action
of LXRa, or the reduced expression of intestinal IBABP
causing a decreased return of bile acids to the liver, will
have to be determined. Regardless of the phenotype
of FXR2/2 mice, this body of work represents a major
advance in lipid biology. Like any series of important
findings, it raises additional questions and provides the
tools with which to answer them.
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